With a $30 million carrot dangling, Phase 3 trials underway in Japan for Cempra's pneumonia drug

Phase 3 trials are underway for Cempra ’s pneumonia drug solithromycin in Japan. The trials are being completed by Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation. To date, the Chapel Hill-based drug developer has received $40 million upfront and in milestone payments from Toyama, which completed a Phase 2 stu dy for solithromycin in Japan earlier this year, according to a release issued by Cempra. The company also said it stands to reap $30 million more in milestone payments…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news